Company intelligence / Profile preview

Milu Labs

New York, New York, United States of Americaprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Milu Labs has developed two innovative diagnostic platforms for women's health—one leveraging exosomes for predictive risk analysis and another integrating multiomics data with artificial intelligence to provide actionable clinical insights. The company is collaborating with global academic institutions and American healthcare companies to advance these technologies. No specific clinical trial results are available as the focus is on diagnostics rather than therapeutics

Therapeutic areas: Women's Health
Modalities: Diagnostic platform (Exosome-based)Diagnostic platform (Multiomics/AI-driven)
Industry: Molecular Diagnostics

Partnerships

Collaborations with global academic institutions and top American healthcare companies are mentioned but not named specifically

Beyond the preview

Go deeper on Milu Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Milu Labs.

Explore the full profile